Literature DB >> 18445663

Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients.

Gian Paolo Rossi1, Anna Belfiore, Giampaolo Bernini, Bruno Fabris, Graziella Caridi, Claudio Ferri, Gilberta Giacchetti, Claudio Letizia, Mauro Maccario, Massimo Mannelli, Gaetana Palumbo, Anna Patalano, Damiano Rizzoni, Ermanno Rossi, Achille C Pessina, Franco Mantero.   

Abstract

CONTEXT: Body mass index (BMI) shows a direct correlation with plasma aldosterone concentration (PAC) and urinary aldosterone excretion in normotensive individuals; whether the same applies to hypertensive patients is unknown.
OBJECTIVE: Our objective was to determine if BMI predicts PAC and the PAC/plasma renin activity ratio [aldosterone renin ratio (ARR)] in hypertensive patients, and if this affects the identification of primary aldosteronism (PA).
DESIGN: This was a prospective evaluation of consecutive hypertensive patients referred nationwide to specialized hypertension centers. MAIN OUTCOME MEASURES: Sitting PAC, plasma renin activity, and the ARR, baseline and after 50 mg captopril orally with concomitant assessment of parameters, including BMI and daily sodium intake, were calculated.
RESULTS: Complete biochemical data and a definite diagnosis were obtained in 1125 consecutive patients. Of them 999 had primary (essential) hypertension (PH) and 126 (11.2%) PA caused by an aldosterone-producing adenoma in 54 (4.8%). BMI independently predicted PAC (beta = 0.153; P < 0.0001) in PH, particularly in the overweight-obese, but not in the PA group. Covariance analysis and formal comparison of the raw, and the BMI-, sex-, and sodium intake-adjusted ARR with receiver operator characteristic curves, showed no significant improvement for the discrimination of aldosterone-producing adenoma from PH patients with covariate-adjusted ARR.
CONCLUSIONS: BMI correlated with PAC independent of age, sex, and sodium intake in PH, but not in PA patients. This association of BMI is particularly evident in overweight-obese PH patients, and suggests a pathophysiological link between visceral adiposity and aldosterone secretion. However, it does not impact on the diagnostic accuracy of the ARR for discriminating PA from PH patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445663     DOI: 10.1210/jc.2008-0251

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  60 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

Review 3.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 4.  A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.

Authors:  J B Byrd; R D Brook
Journal:  J Hum Hypertens       Date:  2013-05-23       Impact factor: 3.012

5.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

6.  Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.

Authors:  R Garg; L Kneen; G H Williams; G K Adler
Journal:  Diabetes Obes Metab       Date:  2013-10-31       Impact factor: 6.577

Review 7.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

8.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

Review 9.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

10.  Increased aldosterone among HIV-infected women with visceral fat accumulation.

Authors:  Janet Lo; Sara E D Looby; Jeffrey Wei; Gail K Adler; Steven K Grinspoon
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.